Be the first person to write a business review for Coating Place, Inc.

Columbia Laboratories, Inc. company was founded in 1986 and is based in Livingston, New Jersey. Columbia Laboratories, Inc. engages in the research, development, and commercialization of women's healthcare and endocrinology products. Its products are used to treat infertility, endometriosis, dysmenorrhea, preterm birth for women with a short cervix at mid-pregnancy, and hormonal deficiencies. The company's products primarily utilize its patented Bioadhesive Delivery System technology. The company markets vaginal progesterone gel products to assist women who are infertile become pregnant in the United States, which include CRINONE 8% for technical procedures to reproductive endocrinologists; PROCHIEVE 8% to obstetricians and gynecologists; and PROCHIEVE 4% for treatment of secondary amenorrhea. It also provides vaginal gel women's products, such as Replens, a vaginal moisturizer for replenishment of vaginal moisture; RepHresh vaginal gel that eliminates vaginal odor; and Advantage-S, a female contraceptive gel. In addition, the company offers STRIANT, a testosterone buccal system for the treatment of hypogonadism in men; and Advance Formula Legatrin PM for the relief of occasional pain and sleeplessness associated with minor muscle aches. Further, it engages in clinical development activities of vaginally-administered lidocaine to prevent and treat dysmenorrhea, as well as vaginally-administered carbamide peroxide for treating vaginal infections; and testosterone progressive hydration vaginal tablet for women, which completed phase I trial.

CyDex Pharmaceuticals, Inc. company was founded in 1993 and is based in Lenexa, Kansas. CyDex Pharmaceuticals, Inc., a pharmaceutical company, engages in the development and commercialization of drugs specifically designed to address limitations of current therapies. It develops a portfolio of product candidates utilizing its drug formulation technology using Captisol, a group of cyclodextrins. The company’s products include Geodon IM and Abilify Injection IM for bipolar disorder/schizophrenia; Vfend IV for antifungal; and Cerenia for canine motion sickness. It also develops Fosphenytoin IV and IM for status epilepticus; Melphalan IV for multiple myeloma; Topiramate IV for epilepsy; Amiodarone IV for arrhythmia; Budesonide Solution Inhalation for asthma; Clopidogrel IV for atherothrombosis; and Budesonide/Azelastine Nasal Spray for allergic rhinitis. In addition, the company out license its technology to third parties for use in the development of their products. CyDex Pharmaceuticals, Inc. was formerly known as CyDex, Inc. and it changed its name in November 2007.

Delcath Systems, Inc. was founded in 1988 and is based in New York, New York. Delcath Systems, Inc., a development stage company, develops and manufactures devices to administer high dose chemotherapy and other therapeutic agents directly to diseased organs or regions of the body. It focuses on the development of the Delcath PHP System, a Phase III clinical trial product, which isolates the liver from the patient's general circulatory system and delivers high dose of melphalan hydrochloride or other therapeutic agents directly to the liver. The Delcath PHP System kit includes an arterial infusion catheter, a multi-passageway/double balloon catheter, a blood tubing/extracorporeal filtration circuit, two activated carbon hemoperfusion filters, a return catheter/a thin-walled blood sheath, and a series of introducers and related accessories to properly place the catheters. The company also conducts Phase II clinical trials to test the Delcath PHP System with the drug melphalan against liver cancer/hepatocellular tumors, neuroendocrine and adenocarcinoma tumors that have spread to the liver, and melanomas metastatic to the liver that have received prior regional treatment. It has a collaboration with the National Cancer Institute to develop and evaluate the Delcath PHP System device to deliver high-dose melphalan to patients, and to evaluate the use of additional chemotherapy agents with the Delcath PHP System.

Elan Corporation, plc company was founded in 1969 and is headquartered in Dublin, Ireland. Elan Corporation, plc (Elan) is a neuroscience-based biotechnology company. Its principal research and development, manufacturing and marketing facilities are located in Ireland and the United States. Elan’s operations are organized into two business units: Biopharmaceuticals and Elan Drug Technologies (EDT). Biopharmaceuticals engages in research, development and commercial activities primarily in neuroscience, autoimmune and severe chronic pain. EDT focuses on the specialty pharmaceutical industry, including specialized drug delivery and manufacturing. In September 2009, the Company and Johnson & Johnson announced that JANSSEN Alzheimer Immunotherapy, a newly formed subsidiary of Johnson & Johnson, has completed the acquisition of substantially all of the assets and rights of Elan related to its Alzheimer`s Immunotherapy Program (AIP).

Emisphere Technologies, Inc. company was founded in 1985. It was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. The company is headquartered in Cedar Knolls, New Jersey. Emisphere Technologies, Inc., a biopharmaceutical company, focuses on the delivery of therapeutic molecules and pharmaceutical compounds using its ‘eligen’ technology. The eligen technology could be applied to the oral route of administration, as well as the other delivery pathways, such as buccal, rectal, inhalation, intra-vaginal, or transdermal. The company’s product pipeline includes Oral Salmon Calcitonin, which is in Phase III clinical trials for the treatment of osteoporosis and osteoarthritis; Oral Recombinant Parathyroid Hormone, which is in Phase I clinical trials for the treatment of osteoporosis; and Oral Heparin that is in Phase III clinical trials, as well as Oral Low Molecular Weight Heparin, which is in Phase I clinical trials for the treatment of cardiovascular diseases. Its products under development also comprise Oral Insulin, which is in Phase II clinical trials, as well as Oral Glucagon-Like Peptides, which is in Phase I clinical trials for the treatment of diabetes; Oral Recombinant Human Growth Hormone that is in Phase I clinical trials for the treatment of growth disorders; and Oral Acyclovir, an anti-viral compound that is in Phase I clinical trials. In addition, the company’s product pipeline consists of Oral PYY 3-36, which is in Phase I clinical trials for treating obesity; Oral Cromolyn Sodium that is in Phase I clinical trials for the treatment of asthma/allergies; and Oral Gallium, a preclinical stage product candidate, for oncology treatment. Emisphere Technologies has collaboration agreements with Novartis Pharma AG; Roche; and Genta, Inc.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.